Evaluating apheresis platelets at reduced dose as a contingency measure for extreme shortages

Background The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage. Study design and methods Using production figures, we mode...

Full description

Saved in:
Bibliographic Details
Published inTransfusion (Philadelphia, Pa.) Vol. 62; no. 1; pp. 173 - 182
Main Authors Smethurst, Peter A., McAndrew, Margaret, Proffitt, Susan, Procter, Simon, Davies, Jane, New, Helen V., Stanworth, Simon J., Doughty, Heidi, Cardigan, Rebecca
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.01.2022
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0041-1132
1537-2995
1537-2995
DOI10.1111/trf.16723

Cover

Abstract Background The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage. Study design and methods Using production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh‐matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage. Results Splitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4. Conclusion A strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages.
AbstractList The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage.BACKGROUNDThe COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage.Using production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh-matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage.STUDY DESIGN AND METHODSUsing production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh-matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage.Splitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4.RESULTSSplitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4.A strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages.CONCLUSIONA strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages.
The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage. Using production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh-matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage. Splitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 10 (~138 ml) and 113 ± 11 × 10 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4. A strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages.
BackgroundThe COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage.Study design and methodsUsing production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh‐matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage.ResultsSplitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4.ConclusionA strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages.
Background The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational impact and effect on platelet quality of splitting units prior to storage. Study design and methods Using production figures, we modeled the impact on unit numbers, platelet counts, and volumes of splitting only apheresis double donations into three units (yielding ⅔ doses), or all standard dose units in half. To assess quality, eight pools of three ABO/Rh‐matched apheresis (Trima Accel) double donations in plasma were split to ⅔ and ½ volumes in both Terumo and Fresenius storage bags. These were irradiated and subject to maximal permitted periods of nonagitation (3 × 8 h) before comparing platelet quality markers (including pH, CD62P expression) to Day 9 of storage. Results Splitting all double donations into three predicted inventory expansion of 23% overall whereas halving all standard dose units clearly doubles stock. In our study, ⅔ and ½ doses contained 153 ± 15 × 109 (~138 ml) and 113 ± 11 × 109 (~102 ml) platelets respectively. Following storage, higher pH was observed in ⅔ than in ½ doses and in Terumo compared to Fresenius bags. The higher pH was reflected in better quality markers, including lower CD62P expression. Despite the differences, on Day 8 (of pH monitoring at expiry) all ⅔ doses and most ½ doses were ≥pH 6.4. Conclusion A strategy to split apheresis platelets in plasma to lower doses is feasible, maintains acceptable platelet quality, and should be considered by blood services in response to extreme shortages.
Author Davies, Jane
New, Helen V.
Smethurst, Peter A.
Proffitt, Susan
Stanworth, Simon J.
McAndrew, Margaret
Cardigan, Rebecca
Procter, Simon
Doughty, Heidi
Author_xml – sequence: 1
  givenname: Peter A.
  orcidid: 0000-0001-6459-1637
  surname: Smethurst
  fullname: Smethurst, Peter A.
  email: peter.smethurst@nhsbt.nhs.uk
  organization: NHS Blood and Transplant
– sequence: 2
  givenname: Margaret
  surname: McAndrew
  fullname: McAndrew, Margaret
  organization: NHS Blood and Transplant
– sequence: 3
  givenname: Susan
  surname: Proffitt
  fullname: Proffitt, Susan
  organization: NHS Blood and Transplant
– sequence: 4
  givenname: Simon
  surname: Procter
  fullname: Procter, Simon
  organization: NHS Blood and Transplant
– sequence: 5
  givenname: Jane
  surname: Davies
  fullname: Davies, Jane
  organization: NHS Blood and Transplant
– sequence: 6
  givenname: Helen V.
  surname: New
  fullname: New, Helen V.
  organization: NHS Blood and Transplant
– sequence: 7
  givenname: Simon J.
  surname: Stanworth
  fullname: Stanworth, Simon J.
  organization: Oxford University Hospitals NHS Foundation Trust
– sequence: 8
  givenname: Heidi
  surname: Doughty
  fullname: Doughty, Heidi
  organization: NHS Blood and Transplant
– sequence: 9
  givenname: Rebecca
  surname: Cardigan
  fullname: Cardigan, Rebecca
  organization: University of Cambridge
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34757639$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtLLDEQhYMoOj4W_gEJuNFFax7TyfRSxBcIguhSQnWnoi3dnTFJ3-v8e6MzbkQLQkHxnUM4Z5usD35AQvY5O-F5TlNwJ1xpIdfIhJdSF6KqynUyYWzKC86l2CLbMb4yxkTF-CbZklNdaiWrCXm6-AfdCKkdninMXzBgbCOdd5CwwxQpJBrQjg1aan1ECvlEGz98CnBoFrRHiGNA6nyg-J4C9kjjiw8JnjHukg0HXcS91d4hj5cXD-fXxe3d1c352W3RyFLKwipktbb51aVis1LVGqzAGqrZVNQcXMksSOsEz2c91Q6k4kKDc5oJJ6XcIUdL33nwbyPGZPo2Nth1MKAfoxFlpZjgM8UyevgDffVjGPLvjFC8YjkVPsvUwYoa6x6tmYe2h7Aw38Fl4HQJNMHHGNCZpk05xpxMgLYznJnPakyuxnxVkxXHPxTfpr-xK_f_bYeLv0HzcH-5VHwA00mdlQ
CitedBy_id crossref_primary_10_1111_trf_18055
crossref_primary_10_1182_blood_2023022593
crossref_primary_10_1182_hematology_2022000379
crossref_primary_10_1080_17474086_2023_2209716
crossref_primary_10_3389_fpubh_2024_1365433
Cites_doi 10.1182/blood-2017-01-759258
10.1111/bjh.14423
10.1111/tme.12312
10.1111/j.1537-2995.2008.01746.x
10.1111/j.1423-0410.1986.tb04849.x
10.1111/trf.12001
10.1111/j.1537-2995.2011.03402.x
10.1111/j.1538-7836.2011.04317.x
10.1111/j.1537-2995.2005.04344.x
10.1182/blood.V64.2.406.406
10.1056/NEJMoa1807320
10.1056/NEJMoa0904084
10.3389/fbioe.2018.00099
10.1111/trf.15036
10.1073/pnas.93.21.11877
10.1056/NEJMoa1212772
10.1016/S2352-3026(20)30186-1
10.1046/j.1365-2141.1997.1572983.x
10.7326/M14-1589
10.1016/S0140-6736(16)30392-0
10.1182/blood-2014-12-617159
10.1046/j.1537-2995.1997.37197176945.x
10.1111/j.1537-2995.2006.00895.x
ContentType Journal Article
Copyright 2021 Crown copyright. Transfusion © 2021 AABB. This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland.
2022 AABB
Copyright_xml – notice: 2021 Crown copyright. Transfusion © 2021 AABB. This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland.
– notice: 2022 AABB
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7U9
8FD
FR3
H94
K9.
P64
7X8
DOI 10.1111/trf.16723
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Virology and AIDS Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1537-2995
EndPage 182
ExternalDocumentID 34757639
10_1111_trf_16723
TRF16723
Genre article
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
123
1OB
1OC
29Q
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5RE
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AAQQT
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBNA
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EGARE
EJD
EMOBN
ESX
EX3
F00
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
H~9
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SJN
SUPJJ
TEORI
TWZ
UB1
UCJ
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YQI
YQJ
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AAYXX
ABJNI
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7U9
8FD
FR3
H94
K9.
P64
7X8
ID FETCH-LOGICAL-c3533-d6e0b7d0b7b560856b7ad2eba9842b1af50da3df21ad2747fa36127aff702f333
IEDL.DBID DR2
ISSN 0041-1132
1537-2995
IngestDate Fri Sep 05 11:03:10 EDT 2025
Wed Aug 13 03:09:09 EDT 2025
Mon Jul 21 06:04:19 EDT 2025
Wed Oct 01 00:48:48 EDT 2025
Thu Apr 24 22:57:46 EDT 2025
Wed Jan 22 16:26:35 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords dose
storage lesion
platelets
Language English
License 2021 Crown copyright. Transfusion © 2021 AABB. This article is published with the permission of the Controller of HMSO and the Queen's Printer for Scotland.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3533-d6e0b7d0b7b560856b7ad2eba9842b1af50da3df21ad2747fa36127aff702f333
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-6459-1637
PMID 34757639
PQID 2619063918
PQPubID 1096380
PageCount 10
ParticipantIDs proquest_miscellaneous_2596021860
proquest_journals_2619063918
pubmed_primary_34757639
crossref_citationtrail_10_1111_trf_16723
crossref_primary_10_1111_trf_16723
wiley_primary_10_1111_trf_16723_TRF16723
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate January 2022
2022-01-00
20220101
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – month: 01
  year: 2022
  text: January 2022
PublicationDecade 2020
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Bethesda
PublicationTitle Transfusion (Philadelphia, Pa.)
PublicationTitleAlternate Transfusion
PublicationYear 2022
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2015; 162
2020; 7
2018; 6
1984; 64
1986; 50
2015; 126
2006; 46
1997; 98
2020
1997; 37
2013; 368
2019; 59
2013; 53
1996; 93
2008; 48
2016; 387
2010; 362
2017; 130
2017; 176
2019; 380
2016; 26
2005; 45
2012; 52
2011; 9
e_1_2_9_30_1
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_10_1
e_1_2_9_13_1
e_1_2_9_12_1
Galloway‐Haskins R (e_1_2_9_9_1) 2013; 53
e_1_2_9_15_1
e_1_2_9_14_1
e_1_2_9_17_1
e_1_2_9_16_1
e_1_2_9_19_1
e_1_2_9_18_1
AABB (e_1_2_9_4_1) 2020
e_1_2_9_20_1
e_1_2_9_22_1
e_1_2_9_21_1
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_5_1
e_1_2_9_3_1
e_1_2_9_2_1
e_1_2_9_26_1
e_1_2_9_25_1
EQDM (e_1_2_9_6_1) 2020
e_1_2_9_28_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 6
  year: 2018
  article-title: Blood‐contacting biomaterials: in vitro evaluation of the hemocompatibility
  publication-title: Front Bioeng Biotechnol
– volume: 52
  start-page: 810
  issue: 4
  year: 2012
  end-page: 8
  article-title: Development of a quality monitoring program for platelet components: a report of the first four years' experience at Canadian Blood Services
  publication-title: Transfusion
– volume: 380
  start-page: 242
  issue: 3
  year: 2019
  end-page: 51
  article-title: Randomized trial of platelet‐transfusion thresholds in neonates
  publication-title: N Engl J Med
– volume: 50
  start-page: 71
  issue: 2
  year: 1986
  end-page: 7
  article-title: Morphological changes associated with pH changes during storage of platelet concentrates in first‐generation 3‐day container
  publication-title: Vox Sang
– volume: 26
  start-page: 177
  issue: 3
  year: 2016
  end-page: 85
  article-title: I am the 9%: making the case for whole‐blood platelets
  publication-title: Transfus Med
– volume: 130
  start-page: 214
  issue: 2
  year: 2017
  end-page: 20
  article-title: The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial
  publication-title: Blood
– volume: 126
  start-page: 1017
  issue: 8
  year: 2015
  end-page: 26
  article-title: Single platelets seal neutrophil‐induced vascular breaches via GPVI during immune‐complex‐mediated inflammation in mice
  publication-title: Blood
– volume: 362
  start-page: 600
  issue: 7
  year: 2010
  end-page: 13
  article-title: Dose of prophylactic platelet transfusions and prevention of hemorrhage
  publication-title: N Engl J Med
– volume: 53
  start-page: 1780
  issue: 8
  year: 2013
  end-page: 7
  article-title: Flow cytometric assessment of agonist‐induced P‐selectin expression as a measure of platelet quality in stored platelet concentrates
  publication-title: Transfusion
– volume: 48
  start-page: 1669
  issue: 8
  year: 2008
  end-page: 75
  article-title: The effect of gamma irradiation on the quality of apheresis platelets during storage for 7 days
  publication-title: Transfusion
– volume: 7
  start-page: e756
  issue: 10
  year: 2020
  end-page: e64
  article-title: Effects of the COVID‐19 pandemic on supply and use of blood for transfusion
  publication-title: Lancet Haematol
– volume: 368
  start-page: 1771
  issue: 19
  year: 2013
  end-page: 80
  article-title: A no‐prophylaxis platelet‐transfusion strategy for hematologic cancers
  publication-title: N Engl J Med
– volume: 64
  start-page: 406
  issue: 2
  year: 1984
  end-page: 14
  article-title: Platelet metabolism during storage of platelet concentrates at 22 degrees C
  publication-title: Blood
– volume: 387
  start-page: 2605
  issue: 10038
  year: 2016
  end-page: 13
  article-title: Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open‐label, phase 3 trial
  publication-title: Lancet
– volume: 93
  start-page: 11877
  issue: 21
  year: 1996
  end-page: 82
  article-title: In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P‐selectin but continue to circulate and function
  publication-title: Proc Natl Acad Sci U S A
– volume: 37
  start-page: 12
  issue: 1
  year: 1997
  end-page: 7
  article-title: The expression of p‐selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability
  publication-title: Transfusion
– volume: 53
  year: 2013
  article-title: Platelet dosing, suspension medium and inter‐transfusion interval
  publication-title: Tranfusion
– volume: 45
  start-page: 773
  issue: 5
  year: 2005
  end-page: 8
  article-title: The value of pH as a quality control indicator for apheresis platelets
  publication-title: Transfusion
– year: 2020
– volume: 46
  start-page: 1300
  issue: 8
  year: 2006
  end-page: 5
  article-title: In vitro pH effects on in vivo recovery and survival of platelets: an analysis by the BEST Collaborative
  publication-title: Transfusion
– volume: 59
  start-page: 779
  issue: 2
  year: 2019
  end-page: 88
  article-title: The argument(s) for lowering the US minimum required content of apheresis platelet components
  publication-title: Transfusion
– volume: 98
  start-page: 86
  issue: 1
  year: 1997
  end-page: 95
  article-title: Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods
  publication-title: Br J Haematol
– volume: 176
  start-page: 365
  issue: 3
  year: 2017
  end-page: 94
  article-title: Guidelines for the use of platelet transfusions
  publication-title: Br J Haematol
– volume: 9
  start-page: 56
  issue: Suppl 1
  year: 2011
  end-page: 65
  article-title: How platelets safeguard vascular integrity
  publication-title: J Thromb Haemost
– volume: 162
  start-page: 205
  issue: 3
  year: 2015
  end-page: 13
  article-title: Platelet transfusion: a clinical practice guideline from the AABB
  publication-title: Ann Intern Med
– ident: e_1_2_9_21_1
  doi: 10.1182/blood-2017-01-759258
– volume-title: Guide to the preparation, use and quality assurance of blood components
  year: 2020
  ident: e_1_2_9_6_1
– ident: e_1_2_9_10_1
  doi: 10.1111/bjh.14423
– ident: e_1_2_9_31_1
– volume: 53
  start-page: S53‐030H0
  year: 2013
  ident: e_1_2_9_9_1
  article-title: Platelet dosing, suspension medium and inter‐transfusion interval
  publication-title: Tranfusion
– ident: e_1_2_9_11_1
  doi: 10.1111/tme.12312
– ident: e_1_2_9_25_1
  doi: 10.1111/j.1537-2995.2008.01746.x
– ident: e_1_2_9_13_1
  doi: 10.1111/j.1423-0410.1986.tb04849.x
– ident: e_1_2_9_18_1
  doi: 10.1111/trf.12001
– ident: e_1_2_9_19_1
  doi: 10.1111/j.1537-2995.2011.03402.x
– ident: e_1_2_9_24_1
  doi: 10.1111/j.1538-7836.2011.04317.x
– ident: e_1_2_9_15_1
  doi: 10.1111/j.1537-2995.2005.04344.x
– ident: e_1_2_9_16_1
  doi: 10.1182/blood.V64.2.406.406
– ident: e_1_2_9_29_1
  doi: 10.1056/NEJMoa1807320
– volume-title: Standards for blood banks and transfusion services
  year: 2020
  ident: e_1_2_9_4_1
– ident: e_1_2_9_27_1
  doi: 10.1056/NEJMoa0904084
– ident: e_1_2_9_12_1
  doi: 10.3389/fbioe.2018.00099
– ident: e_1_2_9_2_1
– ident: e_1_2_9_7_1
  doi: 10.1111/trf.15036
– ident: e_1_2_9_22_1
  doi: 10.1073/pnas.93.21.11877
– ident: e_1_2_9_28_1
  doi: 10.1056/NEJMoa1212772
– ident: e_1_2_9_5_1
– ident: e_1_2_9_8_1
– ident: e_1_2_9_3_1
  doi: 10.1016/S2352-3026(20)30186-1
– ident: e_1_2_9_17_1
  doi: 10.1046/j.1365-2141.1997.1572983.x
– ident: e_1_2_9_26_1
  doi: 10.7326/M14-1589
– ident: e_1_2_9_30_1
  doi: 10.1016/S0140-6736(16)30392-0
– ident: e_1_2_9_23_1
  doi: 10.1182/blood-2014-12-617159
– ident: e_1_2_9_20_1
  doi: 10.1046/j.1537-2995.1997.37197176945.x
– ident: e_1_2_9_14_1
  doi: 10.1111/j.1537-2995.2006.00895.x
SSID ssj0002901
Score 2.3854215
Snippet Background The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the...
The COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the operational...
BackgroundThe COVID19 pandemic highlights the need for contingency planning in the event of blood shortages. To increase platelet supply, we assessed the...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 173
SubjectTerms ABO system
Apheresis
Bags
Blood
Blood platelets
Blood Platelets - metabolism
Blood Preservation
Contingency
COVID-19
dose
Humans
Markers
Pandemics
pH effects
Platelet Count
Plateletpheresis
Platelets
Production methods
Quality assessment
Shortages
Splitting
Storage
Storage containers
storage lesion
Title Evaluating apheresis platelets at reduced dose as a contingency measure for extreme shortages
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ftrf.16723
https://www.ncbi.nlm.nih.gov/pubmed/34757639
https://www.proquest.com/docview/2619063918
https://www.proquest.com/docview/2596021860
Volume 62
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0041-1132
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1537-2995
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002901
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hDhWXFuhrKSCDeuglq9iOk6w4VYgVqgQHBBKHVpGftCrNok32AL--M86jpQ-p6iFSlIxlx_bE38x4PgO8TbVwVpUuyXIRksy5kJRWukTOJOee6Fw05TufneenV9mHa3W9BkdDLkzHDzE63Egz4v-aFFyb5iclb5dhyvNCENMnlyqGaC9-UEdRfLCLLvOETlPvWYVoF89Y8vFa9BvAfIxX44IzfwYfh6Z2-0y-TletmdqHX1gc__NbNuFpD0TZ-27mbMGar7fhyVkfan8On056HvD6hmniHvDNl4bd3SI2xaFumG7ZkmhfvWNu0Xim8RGjje8xW8ves2-d95EhKma4ApAfkjWfCe3f-OYFXM1PLo9Pk_4shsRKRISJy31qCoeXQYxUqtwU2glv9KzMhOE6qNRp6YLg-BhNlKAlYqdCh1CkIkgpX8J6vaj9a2BYUNnUGseVR-NwRox6hdLcWxNEZrIJvBtGpbI9UTmdl3FbDQYLdlcVu2sCh6PoXcfO8Seh3WFoq15Bm4oMR0JnvJzAwfgaVYviJbr2ixXKKDTv6MyudAKvuikx1iKzAi01OcPGxoH9e_XV5cU83uz8u-gb2BCUZhFdPbuw3i5Xfg_BT2v24yz_DmpUAJw
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVoJeaHmVpS01iAOXrGI7r5W4VNDVAt0eqq3USxX5WRAlW22yB_j1zOTVF5UQh0hRYsuOxxN_M2N_A_AuVMKaOLNBlAgfRNb6IDPSBnIkOXdE56LovPP0KJmcRF9O49MV-NCdhWn4IXqHG2lG_b8mBSeH9DUtrxZ-yJNUyAewRvE5UstPx1fkURQhbOLLPKB86i2vEO3j6aveXI3uQMybiLVecsYbcNZ1ttlp8mO4rPTQ_L7F4_i_X7MJj1ssyvabyfMEVlzxFB5O22j7Mzg7aKnAi3OmiH7Ald9LdnmB8BSlXTJVsQUxvzrL7Lx0TOEjRnvf6wNb5hf72TggGQJjhosAuSJZ-Y0A_7krn8PJ-GD2cRK06RgCIxEUBjZxoU4tXhphUhYnOlVWOK1GWSQ0Vz4OrZLWC46P0UrxSiJ8SpX3aSi8lPIFrBbzwr0EhhVjExpteezQPhwRqV4aK-6M9iLS0QDed2LJTctVTikzLvLOZsHhyuvhGsDbvuhlQ9Dxt0I7nWzzVkfLnGxHAmg8G8Cb_jVqF4VMVOHmSywTo4VHabvCAWw1c6JvRUYpGmtyhJ2tJXt_8_nseFzfvPr3onvwaDKbHuaHn4--bsO6oFMXtednB1arxdLtIhaq9Ot6yv8BaX8EuA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkFAvFPrcFqhb9dBLVrGd14oTAlbQAqoQSBxaRX7SCppdbbKH9tczkxePUqnqIVKU2LLj8cTfzNjfAHwIlbAmzmwQJcIHkbU-yIy0gRxJzh3RuSg673x0nOyfRZ_O4_MF2OrOwjT8EL3DjTSj_l-Tgk-tv6Xk1cwPeZIK-QiWogStK0JEJzfcURQgbMLLPKB06i2tEG3j6aveXYz-QJh3AWu94oyfwNeur81Gk8vhvNJD8_sejeN_fswqrLRIlG03U2cNFlzxFJaP2lj7M_i21xKBFxdMEfmAK3-UbHqF4BRlXTJVsRnxvjrL7KR0TOEjRjvf6-Na5hf72bgfGcJihksAOSJZ-Z3g_oUrn8PZeO90Zz9okzEERiIkDGziQp1avDSCpCxOdKqscFqNskhornwcWiWtFxwfo43ilUTwlCrv01B4KeULWCwmhXsFDCvGJjTa8tihdTgiSr00VtwZ7UWkowF87KSSm5apnBJmXOWdxYLDldfDNYD3fdFpQ8_xUKH1TrR5q6FlTpYjwTOeDeBd_xp1iwImqnCTOZaJ0b6jpF3hAF42U6JvRUYpmmpyhJ2tBfv35vPTk3F98_rfi76F5S-74_zw4PjzG3gs6MhF7fZZh8VqNncbCIQqvVlP-Gte7QNn
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+apheresis+platelets+at+reduced+dose+as+a+contingency+measure+for+extreme+shortages&rft.jtitle=Transfusion+%28Philadelphia%2C+Pa.%29&rft.au=Smethurst%2C+Peter+A&rft.au=McAndrew%2C+Margaret&rft.au=Proffitt%2C+Susan&rft.au=Procter%2C+Simon&rft.date=2022-01-01&rft.eissn=1537-2995&rft.volume=62&rft.issue=1&rft.spage=173&rft_id=info:doi/10.1111%2Ftrf.16723&rft_id=info%3Apmid%2F34757639&rft.externalDocID=34757639
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-1132&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-1132&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-1132&client=summon